Floatz logo

eci830

Advanced HR+/HER2- Breast Cancer

Novartis PharmaceuticalsPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

11 Active assets in the Advanced HR+/HER2- Breast Cancer cohort.

Asset / SponsorPhaseRating
FILGRASTIM
MedSIR
Phase 2B
Loperamide
MedSIR
Phase 2B
Atropine
MedSIR
Phase 2CCC
FULVESTRANT
Novartis Pharmaceuticals
Phase 1/2CCC
Letrozole
Novartis Pharmaceuticals
Phase 1/2CCC

View all 11 →

Same molecule, other indications

eci830 is also rated in:

Advanced CCNE1-amplified Solid TumorsDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →